Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 03, 2022

SELL
$7.94 - $12.96 $37,318 - $60,912
-4,700 Reduced 20.62%
18,088 $191,000
Q4 2021

Feb 08, 2022

BUY
$9.93 - $15.39 $35,748 - $55,404
3,600 Added 18.76%
22,788 $321,000
Q2 2021

Aug 03, 2021

BUY
$18.57 - $35.68 $66,852 - $128,448
3,600 Added 23.09%
19,188 $511,000
Q1 2021

Apr 29, 2021

SELL
$31.0 - $55.72 $3.29 Million - $5.91 Million
-106,000 Reduced 87.18%
15,588 $541,000
Q3 2020

Nov 13, 2020

BUY
$40.47 - $45.5 $105,222 - $118,300
2,600 Added 2.19%
121,588 $5 Million
Q2 2020

Aug 13, 2020

BUY
$32.57 - $42.83 $1.07 Million - $1.41 Million
32,988 Added 38.36%
118,988 $4.82 Million
Q1 2020

May 14, 2020

BUY
$23.3 - $45.96 $466,000 - $919,200
20,000 Added 30.3%
86,000 $2.99 Million
Q4 2019

Feb 14, 2020

SELL
$34.58 - $48.06 $4.5 Million - $6.25 Million
-130,000 Reduced 66.33%
66,000 $2.83 Million
Q3 2019

Oct 31, 2019

SELL
$36.98 - $48.45 $1.11 Million - $1.45 Million
-30,000 Reduced 13.27%
196,000 $7.25 Million
Q2 2019

Jul 12, 2019

SELL
$35.13 - $55.53 $1.41 Million - $2.22 Million
-40,000 Reduced 15.04%
226,000 $10.2 Million
Q1 2019

May 10, 2019

SELL
$42.83 - $59.91 $3.49 Million - $4.88 Million
-81,400 Reduced 23.43%
266,000 $14.5 Million
Q4 2018

Jan 31, 2019

BUY
$37.97 - $60.16 $5.98 Million - $9.47 Million
157,400 Added 82.84%
347,400 $16.1 Million
Q3 2018

Oct 19, 2018

BUY
$56.3 - $67.25 $1.01 Million - $1.21 Million
18,000 Added 10.47%
190,000 $11.5 Million
Q2 2018

Jul 11, 2018

BUY
$44.9 - $64.95 $269,400 - $389,700
6,000 Added 3.61%
172,000 $10.8 Million
Q1 2018

May 18, 2018

BUY
$45.35 - $61.65 $90,700 - $123,300
2,000 Added 1.22%
166,000 $7.67 Million
Q4 2017

Feb 08, 2018

SELL
$41.95 - $60.1 $1.47 Million - $2.1 Million
-35,000 Reduced 17.59%
164,000 $7.77 Million
Q3 2017

Oct 24, 2017

BUY
$33.4 - $53.9 $6.65 Million - $10.7 Million
199,000
199,000 $10.7 Million

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $32.8M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Handelsbanken Fonder Ab Portfolio

Follow Handelsbanken Fonder Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.